1.Advances in research on biomaterials and stem cell/exosome-based strategies in the treatment of traumatic brain injury.
Wenya CHI ; Yingying HE ; Shuisheng CHEN ; Lingyi GUO ; Yan YUAN ; Rongjie LI ; Ruiyao LIU ; Dairan ZHOU ; Jianzhong DU ; Tao XU ; Yuan YU
Acta Pharmaceutica Sinica B 2025;15(7):3511-3544
Traumatic brain injury (TBI) is intricately linked to the most severe clinical manifestations of brain damage. It encompasses dynamic pathological mechanisms, including hemodynamic disorders, excitotoxic injury, oxidative stress, mitochondrial dysfunction, inflammation, and neuronal death. This review provides a comprehensive analysis and summary of biomaterial-based tissue engineering scaffolds and nano-drug delivery systems. As an example of functionalized biomaterials, nano-drug delivery systems alter the pharmacokinetic properties of drugs. They provide multiple targeting strategies relying on factors such as morphology and scale, magnetic fields, pH, photosensitivity, and enzymes to facilitate the transport of therapeutics across the blood-brain barrier and to promote selective accumulation at the injury site. Furthermore, therapeutic agents can be incorporated into bioscaffolds to interact with the biochemical and biophysical environment of the brain. Bioscaffolds can mimic the extracellular matrix environment, regulate cellular interactions, and increase the effectiveness of local treatments following surgical interventions. Additionally, stem cell-based and exosome-dominated extracellular vesicle carriers exhibit high bioreactivity and low immunogenicity and can be used to design therapeutic agents with high bioactivity. This review also examines the utilization of endogenous bioactive materials in the treatment of TBI.
2.Immune checkpoint inhibitors-associated myocarditis in 7 patients with bladder cancer
Rongjie BAI ; Xiao YANG ; Hao YU ; Lingkai CAI ; Chenghao WANG ; Qiang CAO ; Qiang LYU
Journal of Modern Urology 2025;30(10):848-853
Objective To explore the clinical characteristics and treatment of immune checkpoint inhibitors(ICIs)-associated myocarditis in patients with bladder cancer(BCa).Methods Clinical and follow-up data of 213 BCa patients treated with ICIs in our hospital during Jan.2020 and May 2024 were collected.The data of 7 patients(3.3%)who developed ICIs-associated myocarditis were analyzed.Results The cohort included 2 females and 5 males(median age:72 years).Four patients were asymptomatic,while 3 presented with chest tightness,dyspnea,or orthopnea.All patients showed significantly elevated high-sensitivity troponin T.Only 2 patients had markedly increased N-terminal pro-B-type natriuretic peptide.Electrocardiograms were normal in 4 patients,while 2 patients exhibited significantly reduced left ventricular global longitudinal strain on echocardiography,with cardiac magnetic resonance confirming acute myocarditis.All patients discontinued ICIs and received first-line methylprednisolone upon diagnosis.Two patients showed no improvement after 5 days of treatment and received second-line therapy.One patient received intravenous immunoglobulin and infliximab without response,but improved after third-line tofacitinib.One patient developed acute respiratory failure after intravenous immunoglobulin administration and was then transferred to ICU,and died of multiple organ failure after 10 days.Conclusion ICIs-associated myocarditis is a relatively rare but clinically distinct immune-related adverse reaction during BCa treatment.Methylprednisolone is the first-line therapy,while critically ill and steroid-resistant patients often require early combined immunosuppressants based on individualized multidisciplinary discussion.
3.Application of NeoVI-RADS scoring in patients with bladder cancer undergoing neoadjuvant therapy
Lingkai CAI ; Xiao YANG ; Zhengye TAN ; Rongjie BAI ; Chenghao WANG ; Chang CHEN ; Qikai WU ; Hao YU ; Chenjiang WU ; Qiang LYU ; Qiang CAO
Chinese Journal of Surgery 2025;63(12):1111-1117
Objective:To evaluate the utility of neoadjuvant vesical imaging-reporting and data system (NeoVI-RADS) in predicting tumor residuals and diagnosing muscle-invasive bladder cancer (MIBC) in patients undergoing neoadjuvant therapy, as well as its application in prognostic stratification.Methods:A retrospective case series analysis was conducted on the clinical data of 91 patients with bladder cancer who received neoadjuvant therapy at the Department of Urology, First Affiliated Hospital of Nanjing Medical University from July 2014 to June 2024. There were 84 male cases and 7 female cases, with an age of (66±9) years (range:45 to 85 years). The clinical staging of the patients was ≥T2 based on imaging. All of them underwent three or more cycles of neoadjuvant therapy, and had post-treatment multiparametric MRI (mp-MRI) evaluation. Based on the results of mp-MRI, the NeoVI-RADS was established and employed to assess tumor residuals and muscle invasion. The receiver operating characteristic curve was plotted, and the area under the curve (AUC) was calculated. Kaplan-Meier survival curves based on overall survival (OS) and cancer-specific survival (CSS) were plotted, and the Log-rank test was used for survival analysis comparison between groups.Results:In the neoadjuvant treatment cohort, the AUC for predicting tumor residuals post-neoadjuvant therapy using NeoVI-RADS was 0.900, with an accuracy of 93.4%, sensitivity of 95.8%, and a specificity of 85.0%. The NeoVI-RADS demonstrated strong diagnostic performance for MIBC, achieving an AUC of 0.900. At a NeoVI-RADS score cutoff of 4, the accuracy was 84.5%, with a sensitivity of 87.5% and a specificity of 72.9%. Additionally, compared to patients with NeoVI-RADS scores of 0 (5-year OS and CSS rates both 100%) or scores of 1 to 3 (5-year OS and CSS rates both 90.9%), patients with scores of 4 to 5 had significantly worse OS (5-year rate 63.0%) and CSS (5-year rate 66.3%) (all P<0.05). There was no statistically significant difference in OS or CSS between patients with NeoVI-RADS scores of 0 and those with scores of 1 to 3 (all P>0.05). Conclusion:NeoVI-RADS demonstrates significant diagnostic and prognostic value in the context of neoadjuvant treatment for bladder cancer, effectively assessing tumor residuals and muscle invasion, thereby enhancing patient management and facilitating personalized treatment approaches.
4.Immune checkpoint inhibitors-associated myocarditis in 7 patients with bladder cancer
Rongjie BAI ; Xiao YANG ; Hao YU ; Lingkai CAI ; Chenghao WANG ; Qiang CAO ; Qiang LYU
Journal of Modern Urology 2025;30(10):848-853
Objective To explore the clinical characteristics and treatment of immune checkpoint inhibitors(ICIs)-associated myocarditis in patients with bladder cancer(BCa).Methods Clinical and follow-up data of 213 BCa patients treated with ICIs in our hospital during Jan.2020 and May 2024 were collected.The data of 7 patients(3.3%)who developed ICIs-associated myocarditis were analyzed.Results The cohort included 2 females and 5 males(median age:72 years).Four patients were asymptomatic,while 3 presented with chest tightness,dyspnea,or orthopnea.All patients showed significantly elevated high-sensitivity troponin T.Only 2 patients had markedly increased N-terminal pro-B-type natriuretic peptide.Electrocardiograms were normal in 4 patients,while 2 patients exhibited significantly reduced left ventricular global longitudinal strain on echocardiography,with cardiac magnetic resonance confirming acute myocarditis.All patients discontinued ICIs and received first-line methylprednisolone upon diagnosis.Two patients showed no improvement after 5 days of treatment and received second-line therapy.One patient received intravenous immunoglobulin and infliximab without response,but improved after third-line tofacitinib.One patient developed acute respiratory failure after intravenous immunoglobulin administration and was then transferred to ICU,and died of multiple organ failure after 10 days.Conclusion ICIs-associated myocarditis is a relatively rare but clinically distinct immune-related adverse reaction during BCa treatment.Methylprednisolone is the first-line therapy,while critically ill and steroid-resistant patients often require early combined immunosuppressants based on individualized multidisciplinary discussion.
5.Application of NeoVI-RADS scoring in patients with bladder cancer undergoing neoadjuvant therapy
Lingkai CAI ; Xiao YANG ; Zhengye TAN ; Rongjie BAI ; Chenghao WANG ; Chang CHEN ; Qikai WU ; Hao YU ; Chenjiang WU ; Qiang LYU ; Qiang CAO
Chinese Journal of Surgery 2025;63(12):1111-1117
Objective:To evaluate the utility of neoadjuvant vesical imaging-reporting and data system (NeoVI-RADS) in predicting tumor residuals and diagnosing muscle-invasive bladder cancer (MIBC) in patients undergoing neoadjuvant therapy, as well as its application in prognostic stratification.Methods:A retrospective case series analysis was conducted on the clinical data of 91 patients with bladder cancer who received neoadjuvant therapy at the Department of Urology, First Affiliated Hospital of Nanjing Medical University from July 2014 to June 2024. There were 84 male cases and 7 female cases, with an age of (66±9) years (range:45 to 85 years). The clinical staging of the patients was ≥T2 based on imaging. All of them underwent three or more cycles of neoadjuvant therapy, and had post-treatment multiparametric MRI (mp-MRI) evaluation. Based on the results of mp-MRI, the NeoVI-RADS was established and employed to assess tumor residuals and muscle invasion. The receiver operating characteristic curve was plotted, and the area under the curve (AUC) was calculated. Kaplan-Meier survival curves based on overall survival (OS) and cancer-specific survival (CSS) were plotted, and the Log-rank test was used for survival analysis comparison between groups.Results:In the neoadjuvant treatment cohort, the AUC for predicting tumor residuals post-neoadjuvant therapy using NeoVI-RADS was 0.900, with an accuracy of 93.4%, sensitivity of 95.8%, and a specificity of 85.0%. The NeoVI-RADS demonstrated strong diagnostic performance for MIBC, achieving an AUC of 0.900. At a NeoVI-RADS score cutoff of 4, the accuracy was 84.5%, with a sensitivity of 87.5% and a specificity of 72.9%. Additionally, compared to patients with NeoVI-RADS scores of 0 (5-year OS and CSS rates both 100%) or scores of 1 to 3 (5-year OS and CSS rates both 90.9%), patients with scores of 4 to 5 had significantly worse OS (5-year rate 63.0%) and CSS (5-year rate 66.3%) (all P<0.05). There was no statistically significant difference in OS or CSS between patients with NeoVI-RADS scores of 0 and those with scores of 1 to 3 (all P>0.05). Conclusion:NeoVI-RADS demonstrates significant diagnostic and prognostic value in the context of neoadjuvant treatment for bladder cancer, effectively assessing tumor residuals and muscle invasion, thereby enhancing patient management and facilitating personalized treatment approaches.
6.Clinical efficacy of endovascular interventional therapy for spontaneous isolated superior mesen-teric artery dissection
Yu LI ; Rongjie ZHANG ; Wei SUN ; Yuxuan XIAO ; Xianru BI ; Yingxue HAO
Chinese Journal of Digestive Surgery 2024;23(6):845-852
Objective:To investigate the clinical efficacy of endovascular interventional therapy for spontaneous isolated superior mesenteric artery dissection(SISMAD).Methods:The retrospective cohort study was conducted. The clinical data of 87 patients with SISMAD who were admitted to The First Affiliated Hospital of Army Medical University from March 2012 to March 2023 were collected. There were 80 males and 7 femals, aged 54(49,61)years. Of 87 patients, 55 cases undergoing conservative therapy were allocated into conservative therapy group and 32 cases under-going endovascular interventional therapy were allocated into endovascular interventional therapy group. Observation indicators: (1) clinical characteristics; (2) treatment; (3) follow-up. Measurement data with normal distribution were represented as Mean± SD, and comparison between groups was conducted using the t test. Measurement data with skewed distribution were represented as M( Q1, Q3), and comparison between groups was conducted using the rank sum test. Count data were represented as absolute numbers and comparison between groups was conducted using the chi-square test or Fisher exact probability. Results:(1) clinical characteristics. There were significant differences in the cases with symptoms, percentage of neutrophils between the conservative therapy group and the endovascular interventional therapy group ( P<0.05). There was no significant difference in the proportion of Yun classification between the two groups ( P>0.05). (2)Treatment. There were significant differences in the complete vascular remodeling, duration of hospital stay, and total expenses between the conservative therapy group and the endovascular interventional therapy group ( χ2=23.752, t=-4.213, -16.421, P<0.05). There were 34 patients in the conservative therapy group and 24 patients in the endovascular interventional therapy group with relieved abdominal pain, respectively, showing no significant difference between the two groups ( P>0.05). For symptomatic patients in the conservative therapy group, symptoms including abdominal pain, nausea, vomiting, diarrhea, hematochezia were relieved or disappeared, and no intestinal ischemia or rupture occurred. For patients in the endovascular interventional therapy group, 30 cases were implanted stents, the operation time was 115(86,155)minutes, volume of intraoperative blood loss was 5(5,10)mL, dose of contrast media was (200±51)mL. There were 23, 8 and 1 cases with the contrast medium as Iodoxanol, Ioprosamide, Iodohexanol, respectively. About the surgical methods, 14 patients received single bare stent implantation, 3 cases received bare stent-assisted coil embolization, 10 cases received multiple bare stent implantation, 3 cases received covered stent implantation, 2 cases received angiography alone. A total of 39 self-expandable bare metal stents and 3 self-expandable covered stents were implanted. The diameter and length of the stents were (6.5±1.0)mm and (69±23)mm, respectively. Two asymptomatic patients had failure in endovascular interventional therapy and underwent superior mesenteric artery angiography. For the endovascular interventional therapy group, 92.3%(24/26) of patients were relieved abdominal pain and 2 patients with abdominal pain were improved after symptomatic treatment. (3) Follow-up. All the 87 patients were followed up for 12(4,24)months, without recurrent abdominal pain or secondary intervention. During the follow-up, 82 patients underwent computed tomography angiography or ultrasonography, and 5 patients had no available results. There was no SISMAD related death or superior mesenteric artery rupture. Eight patients in the conservative therapy group achieved complete vascular remodeling, versus 21 cases in the endovascular interventional therapy group, showing a significant difference between the two groups ( χ2=23.752, P<0.05). Conclusions:Compared with conservative therapy, patients undergoing endovascular interventional therapy for SISMAD has loner hospital stay, higher total costs, higher complete vascular remodeling rate. There is no recurrent abdominal pain in two methods.
7.Meta-analysis of Next-generation Sequencing in the Etiological Diagnosis of Sepsis Patients
Rongjie YU ; Yingchen WANG ; Qi LIANG
Journal of Medical Research 2023;52(12):134-140
Objective To systematically evaluate the application value of next-generation sequencing technology in the etiological diagnosis of patients with sepsis.Methods Databases such as PubMed,Embase,Web of Science,The Cochrane Library,VIP,CNKI,WanFang Data Knowledge Service platform and SinoMed were searched from January 2018 to September 2022.The positive rate of sepsis detection,pathogen detection time,virus detection rate,28 days mortality rate and length of stay in intensive care unit(ICU)were com-pared between next-generation sequencing technology and traditional etiological detection method.Meta-analysis was performed using Review Manager 5.4.1 software,and funnel plot was pictured to analyze the publication bias of the included literatures.Results A total of 18 literatures were included.The results of Meta-analysis showed that the positive rate of next-generation sequencing group was 72.3%(1403/1941),which was significantly higher than that of the traditional etiological detection group[28.4%(556/1958),OR=7.03,95%CI:4.52-10.95,P<0.01];the time of pathogen detection was significantly lower than that of traditional etiological detec-tion group(OR=-34.22,95%CI:-41.95--26.48,P<0.01);the virus detection rate was significantly higher than that of tradi-tional etiological detection group(OR=57.82,95%CI:19.27-173.46,P<0.01);the length of stay in ICU was significantly lower than that of traditional etiological detection group(WMD=-9.37,95%CI:-16.28--2.46,P<0.01);there was no significant difference in 28 days mortality between the two groups(OR=0.43,95%CI:0.02-8.47,P=0.58).Conclusion Compared with tra-ditional etiological detection methods,next-generation sequencing technology can improve the positive rate of pathogen detection and vi-rus detection in sepsis patients,shorten the time of pathogen physical examination and the length of stay in ICU,and has higher applica-tion value for the diagnosis and treatment of sepsis.
8.Relationship among depression,anxiety and social support in elderly patients from community outpa-tient clinic
Leping HUANG ; Ruyan HUANG ; Zuowei WANG ; Zhiguo WU ; Yue FEI ; Weiyun XU ; Jinxia XIONG ; Shans-Han XU ; Rongjie MAO ; Fei YU ; Yiru FANG
Chinese Journal of Behavioral Medicine and Brain Science 2019;28(7):580-585
Objective To explore the relationship among depression,anxiety and social support in elderly patients in community outpatient clinic. Methods A total of 551 elderly outpatients from two com-munity health service centers of Hongkou District in Shanghai were evaluated with patient health question-naire-9 (PHQ-9),generalized anxiety disorder-7 (GAD-7),perceived social support scale( PSSS) for de-pression,anxiety,physical health and social support. Results The prevalence rates of depression and anxiety were 26. 1% and 17. 2%,respectively. The scores of PHQ-9 and GAD-7 were 2. 0(4. 0) and 1. 0(2. 0). There were statistically significant differences in the scores of family support,friend support,other support and social support among the elderly patients with different degrees of depression or anxiety (P<0. 01). Fam-ily support(B=-0. 196) and friend support(B=-0. 171) were protective factors of depression in elderly pa-tients in community outpatient clinic. Age,family support and friend support were protective factors of anxiety in elderly patients,while gender and fluctuation of physical diseases were protective factors of anxiety(P<0. 05). Con-clusions The depression and anxiety is intimately related to social support in elderly outpatients. Appropriate measures should be taken to optimize social support,mitigate bad mood negative improve their quality of life.
9.Effects of Valpar Component Work Sample on Parkinson's Disease
Liling CUI ; Yang YU ; Yup WANG ; Yuanyuan CHENG ; Rongjie CHEN ; Jialing WU
Chinese Journal of Rehabilitation Theory and Practice 2018;24(7):767-772
Objective To explore the effects of Valpar Component Work Sample on Parkinson's disease (PD). Methods From June, 2015 to June, 2017, 40 patients with PD were randomly divided into control group (n=20) and observation group (n=20). Both groups received routine treatment and occupational therapy, while the observation group accepted rehabilitation with Valpar Component Work Sample in addition, for eight weeks. They were assessed with Unified Parkinson's Disease Rating Score II and III (UPDRSII and UPDRSIII), Mini-Mental State Examination (MMSE), Hamilton Depression Scale (HAMD), Hamilton Anxiety Scale (HAMA) and the Parkinson's Disease Questionnaire-39 (PDQ-39) before and after treatment. Results The scores of UPDRSII, UPDRSIII, MMSE, HAMD, and HAMA, and Summary Index of PDQ-39 improved in both groups (t>2.864, P<0.05) after treatment, and improved more in the observation group than in the control group (t>2.237, P<0.05). Conclusion Combined with Valpar Component Work Sample may further improve the activities of daily living, motor, cognitive function, depression and anxiety, and then quality of life in patients with PD.
10.miR-181b functions as an oncomiR in colorectal cancer by targeting PDCD4.
Yanqing LIU ; UZAIR-UR-REHMAN ; Yu GUO ; Hongwei LIANG ; Rongjie CHENG ; Fei YANG ; Yeting HONG ; Chihao ZHAO ; Minghui LIU ; Mengchao YU ; Xinyan ZHOU ; Kai YIN ; Jiangning CHEN ; Junfeng ZHANG ; Chen-Yu ZHANG ; Feng ZHI ; Xi CHEN
Protein & Cell 2016;7(10):722-734
Programmed cell death 4 (PDCD4) is a RNA-binding protein that acts as a tumor suppressor in many cancer types, including colorectal cancer (CRC). During CRC carcinogenesis, PDCD4 protein levels remarkably decrease, but the underlying molecular mechanism for decreased PDCD4 expression is not fully understood. In this study, we performed bioinformatics analysis to identify miRNAs that potentially target PDCD4. We demonstrated miR-181b as a direct regulator of PDCD4. We further showed that activation of IL6/STAT3 signaling pathway increased miR-181b expression and consequently resulted in downregulation of PDCD4 in CRC cells. In addition, we investigated the biological effects of PDCD4 inhibition by miR-181b both in vitro and in vivo and found that miR-181b could promote cell proliferation and migration and suppress apoptosis in CRC cells and accelerate tumor growth in xenograft mice, potentially through targeting PDCD4. Taken together, this study highlights an oncomiR role for miR-181b in regulating PDCD4 in CRC and suggests that miR-181b may be a novel molecular therapeutic target for CRC.
Animals
;
Apoptosis Regulatory Proteins
;
genetics
;
metabolism
;
Caco-2 Cells
;
Cell Proliferation
;
Colorectal Neoplasms
;
genetics
;
metabolism
;
pathology
;
Heterografts
;
Humans
;
Male
;
Mice
;
Mice, Nude
;
Mice, SCID
;
MicroRNAs
;
genetics
;
metabolism
;
Neoplasm Proteins
;
genetics
;
metabolism
;
Neoplasm Transplantation
;
RNA, Neoplasm
;
genetics
;
metabolism
;
RNA-Binding Proteins
;
genetics
;
metabolism

Result Analysis
Print
Save
E-mail